Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr0.87 DKK
Change Today 0.00 / 0.00%
Volume 389.0K
VELO On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
As of 11:04 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

veloxis pharmaceuticals a/s (VELO) Snapshot

Open
kr0.88
Previous Close
kr0.87
Day High
kr0.89
Day Low
kr0.86
52 Week High
07/4/14 - kr2.30
52 Week Low
04/30/15 - kr0.75
Market Cap
1.4B
Average Volume 10 Days
749.3K
EPS TTM
kr-0.03
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VELOXIS PHARMACEUTICALS A/S (VELO)

Related News

No related news articles were found.

veloxis pharmaceuticals a/s (VELO) Related Businessweek News

No Related Businessweek News Found

veloxis pharmaceuticals a/s (VELO) Details

Veloxis Pharmaceuticals A/S operates as a specialty pharmaceutical company. The company’s proprietary technology, MeltDose is designed to enhance the absorption and bioavailability of select orally administered drugs. Its lead product candidate is Envarsus, a once-daily dosage tablet version of tacrolimus for the treatment of kidney transplant patients. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is headquartered in Hørsholm, Denmark.

30 Employees
Last Reported Date: 05/20/15

veloxis pharmaceuticals a/s (VELO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

veloxis pharmaceuticals a/s (VELO) Key Developments

Veloxis Pharmaceuticals A/S Announces Top-Line Results of the ASTCOFF Study

Veloxis Pharmaceuticals A/S announced top-line results of the ASTCOFF study, ASTeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily tacrolimus (Prograf®) or a once-daily tacrolimus product, Astagraf XL capsules administered once-daily and Prograf capsules administered twice-daily in stable renal transplant patients. Patients were dosed with each drug for seven days and blood samples were obtained over 24 hours to obtain pharmacokinetic data. This study confirmed previously published data for Envarsus and showed greater bioavailability (p<0.0001) and a flatter PK profile characterized by lower peak-to-trough fluctuation (p<0.001) and delayed time to peak concentrations of 6 hrs (p=<0.001) compared to both Prograf and Astagraf. At equivalent exposure, Envarsus achieves at least a 30% dose reduction requirement and a substantively lower peak blood concentration (p=<0.005) compared to the two comparator products.

Veloxis Pharmaceuticals A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Veloxis Pharmaceuticals A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the first quarter of 2015 the company recognized revenue of DKK 4.3 million compared to DKK 12.2 million in the same period of 2014. Operating loss was DKK 46.5 million compared to DKK 22.2 million in the corresponding period of 2014. Net loss was DKK 27.0 million compared to DKK 20.0 million in the corresponding period of 2014. Loss before tax was DKK 28.465 million against DKK 21.490 million a year ago. Basic and diluted LPS was DKK 0.02 against DKK 0.01 a year ago. Cash used in operating activities were DKK 56.494 million against DKK 33.550 million a year ago. Veloxis maintains its 2015 outlook with an operating loss of DKK 200 million to DKK 240 million and a net loss of DKK 195 million to DKK 235 million for the financial year 2015.

Veloxis Pharmaceuticals A/S, Q1 2015 Earnings Call, May 21, 2015

Veloxis Pharmaceuticals A/S, Q1 2015 Earnings Call, May 21, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VELO:DC kr0.87 DKK 0.00

VELO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abzena PLC 86.00 GBp 0.00
Durect Corp $2.39 USD +0.13
Enzon Pharmaceuticals Inc $1.20 USD +0.025
Onxeo SA €4.88 EUR -0.01
Oxford Biomedica PLC 9.15 GBp +0.35
View Industry Companies
 

Industry Analysis

VELO

Industry Average

Valuation VELO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VELOXIS PHARMACEUTICALS A/S, please visit www.veloxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.